Pfizer TALZENNA-XTANDI combo ups Survival in Metastatic Castration Resistant Prostate Cancer
- TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of HRR mutation status
- TALZENNA + XTANDI improved median OS by almost 9 months in unselected patients (Cohort 1) and by 14 months in patients selected for HRR mutations (Cohort 2) versus standard of care XTANDI
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.